Serum amyloid A: A new potential serum marker correlated with the stage of breast cancer

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 940-944

  Zhang, Guojun ^a   Sun, Xudong ^b   Lv, Hong ^a   Yang, Xiaolin ^b   Kang, Xixiong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Beijing Yuande BioMedical Engineering Co Ltd   (China)

Author keywords

Breast cancer; Diagnosis; Serum amyloid A; Staging

Indexed keywords

SERUM AMYLOID A;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY;

EID: 84863173085     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.584     Document Type: Article

References (37)

1. Veronesi U, Boyle P, Goldhirsch A, Orecchia R and Viale G: Breast cancer. Lancet 365: 1727-1741, 2005.
2. Redondo M, Rivas-Ruiz F, Guzman-Soler MC and Labajos C: Monitoring indicators of health care quality by means of a hospital register of tumours. J Eval Clin Pract 14: 1026-1030, 2008.
3. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA and Duffy SW: Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361: 1405-1410, 2003.
4. Elmore JG, Armstrong K, Lehman CD and Fletcher SW: Screening for breast cancer. JAMA 293: 1245-1256, 2005.
5. Ding J, Warren R, Warsi I, et al: Evaluating the effectiveness of using standard mammogram form to predict breast cancer risk: case-control study. Cancer Epidemiol Biomarkers Prev 17: 1074-1081, 2008.
6. Frangioni JV: New technologies for human cancer imaging. J Clin Oncol 26: 4012-4021, 2008.
7. Le L, Chi K, Tyldesley S, et al: Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51: 695-707, 2005.
8. Diamandis EP: Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal carcinoma. Clin Cancer Res 10: 5293; author reply 5293-5294, 2004.
9. Koomen JM, Shih LN, Coombes KR, et al: Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 11: 1110-1118, 2005.
10. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC and Patz EF Jr: Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 3: 1720-1724, 2003.
11. Gao WM, Kuick R, Orchekowski RP, et al: Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 5: 110, 2005.
12. Yokoi K, Shih LC, Kobayashi R, et al: Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 27: 1361-1369, 2005.
13. Dai S, Wang X, Liu L, et al: Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum. Sci China C Life Sci 50: 305-311, 2007.
14. Dowling P, O'Driscoll L, Meleady P., et al: 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 28: 4302-4310, 2007.
15. Cocco E, Bellone S, El-Sahwi K, et al: Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer 101: 335-341, 2009.
16. Cocco E, Bellone S, El-Sahwi K, et al: Serum amyloid A: a novel biomarker for endometrial cancer. Cancer 116: 843-851, 2010
17. Urieli-Shoval S, Linke RP and Matzner Y: Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 7: 64-69, 2000.
18. Gutfeld O, Prus D, Ackerman Z, et al: Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem 54: 63-73, 2006.
19. Liang L, Qu L and Ding Y: Protein and mRNA characterization in human colorectal carcinoma cell lines with different metastatic potentials. Cancer Invest 25: 427-434, 2007.
20. Michaeli A, Finci-Yeheskel Z, Dishon S, Linke RP, Levin M and Urieli-Shoval S: Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. Biochem Biophys Res Commun 368: 368-373, 2008.
21. Malle E, Sodin-Semrl S and Kovacevic A: Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66: 9-26, 2009.
22. Li Y, Cai L, Wang H, et al: Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2. Oncogene 36: 3887-3899, 2011.
23. Paret C, Schon Z, Szponar A and Kovacs G: Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 57: 859-866, 2010.
24. Schaub NP, Jones KJ, Nyalwidhe JO, et al: Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. J Am Coll Surg 208: 970-978, 2009.
25. La Merrill M, Gordon RR, Hunter KW, Threadgill DW and Pomp D: Dietary fat alters pulmonary metastasis of mammary cancers through cancer autonomous and non-autonomous changes in gene expression. Clin Exp Metastasis 27: 107-116, 2010.
26. Pierce BL, Ballard-Barbash R, Bernstein L, et al: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444, 2009.
27. Biran H, Friedman N, Neumann L, Pras M and Shainkin-Kestenbaum R: Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39: 794-797, 1986.
28. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N and Cohen AS: Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 19: 193-198, 1984.
29. Ramankulov A, Lein M, Johannsen M, et al: Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 269: 85-92, 2008.
30. Chan DC, Chen CJ, Chu HC, et al: Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 14: 84-93, 2007.
31. Khan N, Cromer CJ, Campa M and Patz EF Jr: Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 101: 379-384, 2004.
32. Glojnaric I, Casl MT, Simic D and Lukac J: Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 39: 129-133, 2001.
33. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, et al: Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 5: 3790-3797, 2005.
34. Pierce BL, Neuhouser ML, Wener MH, et al: Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 114: 155-167, 2009.
35. George SM, Neuhouser ML, Mayne ST, et al: Postdiagnosis diet quality is inversely related to a biomarker of inflammation among breast cancer survivors. Cancer Epidemiol Biomarkers Prev 19: 2220-2228, 2010.
36. Villasenor A, Ambs A, Ballard-Barbash R, et al: Dietary fiber is associated with circulating concentrations of C-reactive protein in breast cancer survivors: the HEAL study. Breast Cancer Res Treat 129: 485-494, 2011.
37. Sung HJ, Ahn JM, Yoon YH, et al: Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 10: 1383-1395, 2011.